WEKO3
アイテム
{"_buckets": {"deposit": "8fb50835-a74b-43bd-8f9d-96955a4d1b0a"}, "_deposit": {"created_by": 2, "id": "1466", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "1466"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00001466", "sets": ["9"]}, "author_link": ["6981", "6982", "6988", "6983", "6990", "6987", "6986", "6989", "6985", "6980", "6979", "6984"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-12", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "57", "bibliographicPageStart": "50", "bibliographicVolumeNumber": "75", "bibliographic_titles": [{"bibliographic_title": "Leukemia Research"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Atypical chronic myeloid leukemia(aCML)and chronic neutrophilic leukemia(CNL)are rare BCR-ABL1 fusion gene-negative myeloid neoplasms with a predominance of neutrophils. \nSince no standard therapeutic strategy currently exists for these diseases,we retrospectively evaluated the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aCML and CNL. Data from 14 aCML and 5 CNL patients as their diagnoses were collected using a nationwide survey. Allo-HSCT was performed between 2003 and 2014. Preconditioning regimens included myeloablative (n = 15),reduced-intensity (n = 3), and non-myeloablative (n = 1) regimens. Transplanted stem cells were obtained from HLA-matched related donors (n = 5) and alternative donors (n = 14). Neutrophil engraftment was successfully achieved in 17 patients. One-year overall survival rates (OS) were 54.4% (95% confidence interval [CI], 24.8 to 76.7%) and 40.0% (95% CI, 5.2 to 75.3%) in patients with aCML and CNL, respectively. Among aCML patients, 1-year OS were 76.2% (95% CI, 33.2 to 93.5%) and 20.0% (95% CI, 0.8 to 58.2%) in patients with \u003c5% myeloblasts (n = 9) and ?5% myeloblasts (n = 5) in peripheral blood before allo-HSCT, respectively. These results suggest that allo-HSCT achieves long-term survival in patients with aCML and CNL. \nBetter pre-transplant management is required to improve the outcomes of aCML patients with ?5% blasts in peripheral blood.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Leukemia Research, 75, pp.50-57; 2018", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier Ltd."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.leukres.2018.11.003", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c2018, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "01452126", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Itonaga, Hidehiro"}], "nameIdentifiers": [{"nameIdentifier": "6979", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ota, Shuichi"}], "nameIdentifiers": [{"nameIdentifier": "6980", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "6981", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taji, Hirohumi"}], "nameIdentifiers": [{"nameIdentifier": "6982", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Amano, Itsuto"}], "nameIdentifiers": [{"nameIdentifier": "6983", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hasegawa, Yuichi"}], "nameIdentifiers": [{"nameIdentifier": "6984", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichinohe, Tatsuo"}], "nameIdentifiers": [{"nameIdentifier": "6985", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Takahiro"}], "nameIdentifiers": [{"nameIdentifier": "6986", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsuta, Yoshiko"}], "nameIdentifiers": [{"nameIdentifier": "6987", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanizawa, Akihiko"}], "nameIdentifiers": [{"nameIdentifier": "6988", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kondo, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "6989", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Yasushi"}], "nameIdentifiers": [{"nameIdentifier": "6990", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "LR75_50.pdf", "filesize": [{"value": "483.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 483600.0, "url": {"label": "LR75_50.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/1466/files/LR75_50.pdf"}, "version_id": "e94bd2a0-ebf2-43e9-9681-b0309ba27fbc"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Allogeneic hematopoietic stem cell transplantation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Atypical chronic myeloid leukemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Chronic neutrophil leukemia", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/38731", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-01-01"}, "publish_date": "2020-01-01", "publish_status": "0", "recid": "1466", "relation": {}, "relation_version_is_last": true, "title": ["Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan"], "weko_shared_id": -1}
Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan
http://hdl.handle.net/10069/38731
http://hdl.handle.net/10069/387315f41be4d-417f-42ad-bfc9-4156ea40c16a
名前 / ファイル | ライセンス | アクション |
---|---|---|
LR75_50.pdf (483.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-01-01 | |||||
タイトル | ||||||
タイトル | Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Allogeneic hematopoietic stem cell transplantation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Atypical chronic myeloid leukemia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Chronic neutrophil leukemia | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Itonaga, Hidehiro
× Itonaga, Hidehiro× Ota, Shuichi× Ikeda, Takashi× Taji, Hirohumi× Amano, Itsuto× Hasegawa, Yuichi× Ichinohe, Tatsuo× Fukuda, Takahiro× Atsuta, Yoshiko× Tanizawa, Akihiko× Kondo, Takeshi× Miyazaki, Yasushi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Atypical chronic myeloid leukemia(aCML)and chronic neutrophilic leukemia(CNL)are rare BCR-ABL1 fusion gene-negative myeloid neoplasms with a predominance of neutrophils. Since no standard therapeutic strategy currently exists for these diseases,we retrospectively evaluated the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aCML and CNL. Data from 14 aCML and 5 CNL patients as their diagnoses were collected using a nationwide survey. Allo-HSCT was performed between 2003 and 2014. Preconditioning regimens included myeloablative (n = 15),reduced-intensity (n = 3), and non-myeloablative (n = 1) regimens. Transplanted stem cells were obtained from HLA-matched related donors (n = 5) and alternative donors (n = 14). Neutrophil engraftment was successfully achieved in 17 patients. One-year overall survival rates (OS) were 54.4% (95% confidence interval [CI], 24.8 to 76.7%) and 40.0% (95% CI, 5.2 to 75.3%) in patients with aCML and CNL, respectively. Among aCML patients, 1-year OS were 76.2% (95% CI, 33.2 to 93.5%) and 20.0% (95% CI, 0.8 to 58.2%) in patients with <5% myeloblasts (n = 9) and ?5% myeloblasts (n = 5) in peripheral blood before allo-HSCT, respectively. These results suggest that allo-HSCT achieves long-term survival in patients with aCML and CNL. Better pre-transplant management is required to improve the outcomes of aCML patients with ?5% blasts in peripheral blood. |
|||||
書誌情報 |
Leukemia Research 巻 75, p. 50-57, 発行日 2018-12 |
|||||
出版者 | ||||||
出版者 | Elsevier Ltd. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 01452126 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.leukres.2018.11.003 | |||||
権利 | ||||||
権利情報 | c2018, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Leukemia Research, 75, pp.50-57; 2018 |